* Abeona Therapeutics Inc ABEO.OQ ABEO.O is expected
to show a
rise in quarterly revenue when it reports results on November
11 (estimated) for the period ending September 30 2024
* The Cleveland Ohio-based company is expected to report
revenue
of $100 thousand, according to the mean estimate from 5
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Abeona Therapeutics Inc
is for
a loss of 40 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Abeona
Therapeutics Inc is 16.50, above its last closing price
of $6.38.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.39 -0.36 0.19 Beat 152.2
Jan. 1 2024 -0.51 -0.51 -1.16 Missed -126
Dec. 31 2023 -0.47 -0.77 Missed -63.8
Sep. 30 2023 -0.53 -0.53 -0.48 Beat 8.9
Jun. -0.71 -0.68 -0.92 Missed -35.3
30 2023
Mar. 31 2023 -0.62 -0.58 -0.54 Beat 6.9
Dec. 31 2022 -0.75 1.53 Beat 304
Jan. 1 0001 -1.75 -1.75 -1.48 Beat 15.3
This summary was machine generated November 8 at 15:38 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)